INDIANAPOLIS, Oct. 2, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved an additional indication for Jaypirca (pirtobrutinib, 100 mg & 50 mg tablets), a non-covalent Bruton tyrosine kinase (BTK) inhibitor,...
Hence then, the article about lilly s jaypirca pirtobrutinib the first and only approved non covalent btk inhibitor receives expanded indication from u s fda for certain patients with previously untreated cll sll was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Lilly's Jaypirca (pirtobrutinib), the first-and-only approved non-covalent BTK inhibitor, receives expanded indication from U.S. FDA for certain patients with previously untreated CLL/SLL )
Also on site :
- Meta faces $40 bn data privacy penalty
- The Police Frontman, a Former Schoolteacher Whose ‘Every Breath You Take’ Became the Most-Played Song in Radio History, Turns 75
- In ‘Marshals’ Season 2 Premiere, Kayce Dutton Goes Rogue to Save His Son—and Our Exclusive Sneak Peek Offers a First Look at the Action